BioSpace News Archive

Despite affecting up to 15% of women and a $15 billion annual economic burden in the U.S. alone, polycystic ovary syndrome (PCOS) has yet to see any treatments specifically for the disorder approved by the U.S. Food and Drug Administration (FDA).

Harvard Bioscience, Inc. and Etisense announced that they have entered into an agreement to offer DECRO®, Etisense’s non-invasive telemetry jacket and associated physiological monitoring software, to a broad range of pre-clinical customers in the North American and European markets.

VUNO Inc., South Korean medical AI company announced that its AI-based cardiac arrest risk management system, VUNO Med®-DeepCARS™, has proven its clinical validity for the first time through a prospective study utilizing Real World Data(RWD).

Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced a positive interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer’s disease.

Natera, Inc., a global leader in cell-free DNA testing, announced three appointments within its senior leadership team, effective immediately.

Kineta, Inc. (Nasdaq: KA) announced today a research agreement with Fred Hutchinson Cancer Center to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, alone and in combination with pembrolizumab.

Astrea Bioseparations announces the expansion of its manufacturing and warehousing capabilities in the US. The increased capacity reflects growing demand for the Company’s chromatography solutions in North American markets.

OyaGen, Inc. Today the company announced publication in Antiviral Research of studies evaluating the mechanism of action of its proprietary COVID therapeutic in preclinical development.

Hospitalized adult patients whose medical conditions worsen after being admitted, requiring escalation of care, such as transfer to the intensive care unit (ICU) or intervention of a rapid response team, may benefit from monitoring by artificial intelligence (AI).

One in eight women will be diagnosed with breast cancer during their lifetime.